During the last three months, 7 analysts shared their evaluations of Hologic (NASDAQ:HOLX), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Hologic, revealing an average target of $74.57, a high estimate of $87.00, and a low estimate of $68.00. Surpassing the previous average price target of $66.71, the current average has increased by 11.78%.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of Hologic's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $78.00 | $78.00 |
| Conor McNamara | RBC Capital | Raises | Outperform | $87.00 | $72.00 |
| Tejas Savant | Morgan Stanley | Raises | Equal-Weight | $69.00 | $65.00 |
| Elizabeth Garcia | UBS | Raises | Neutral | $70.00 | $65.00 |
| Anthony Petrone | Mizuho | Raises | Outperform | $70.00 | $65.00 |
| Patrick Donnelly | Citigroup | Raises | Buy | $80.00 | $60.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $68.00 | $62.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Hologic's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Hologic analyst ratings.
Unveiling the Story Behind Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Breaking Down Hologic's Financial Performance
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Hologic showcased positive performance, achieving a revenue growth rate of 1.23% as of 30 June, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.04%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE excels beyond industry benchmarks, reaching 4.12%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Hologic's ROA stands out, surpassing industry averages. With an impressive ROA of 2.25%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hologic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
